Lessons from a multicentre retrospective study of peptide receptor radionuclide therapy combined with lanreotide for neuroendocrine tumours: a need for standardised practice.
Vikas PrasadRaj SrirajaskanthanChristos ToumpanakisChiara Maria GranaSergio BaldariTahir ShahAngela LamarcaFrédéric CourbonKlemens ScheidhauerEric BaudinXuan-Mai Truong ThanhAude HouchardClarisse DromainLisa BodeiPublished in: European journal of nuclear medicine and molecular imaging (2020)
Trial number: NCT02788578; URL: https://clinicaltrials.gov/ct2/show/NCT02788578.
Keyphrases
- study protocol
- clinical trial
- primary care
- phase iii
- healthcare
- computed tomography
- image quality
- phase ii
- dual energy
- randomized controlled trial
- contrast enhanced
- double blind
- cross sectional
- open label
- positron emission tomography
- magnetic resonance imaging
- quality improvement
- stem cells
- binding protein
- mesenchymal stem cells
- cell therapy